Please assess the completion status of the following clinical trial:

Trial Title: Relapses in Plasmodium Ovale and Efficacy of Artemether-lumefantrine for Mixed Species and Non-falciparum Malaria

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients older than 1 year~* Presence of uncomplicated malaria infection confirmed by: fever or history of fever in the previous 3 days, and positive microscopy of P. malariae, P. ovale or mixed infection with parasite density \> 10 - 200000/µl of blood~* Residence in vicinity and no travel plans for the next 6 months~* Written informed consent by the patient or the legal representative and where possible, patient assent will be sought. If the patient/parent/guardian is unable to write, witnessed consent is permitted according to local ethical considerations.~Exclusion Criteria:~* Presence of P. falciparum monoinfection~* Presence of severe malaria (clinical WHO criteria)~* Presence of other febrile conditions~* Known history of hypersensitivity, allergic or adverse reactions to artemether or lumefantrine~* Intake of any antimalarials or antibiotics with known antimalarial activity in the past 72 hours~* Intake of an 8-aminoquinoline antimalarial or atovaquone-proguanil in preceding 28 days~* Pregnant women in first trimenon

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Coartem (Type: OTHER): Patients will receive the study drug combination artemether-lumefantrine (Coartem®) orally as a 6 dose regimen for three consecutive days. Tablets are available as a fixed dose combination of 20mg artemether plus 120mg lumefantrine. The dosing will be based on the body weight and follow the manufacturer's recommendations:~Body weight 5-14kg: 1 tablet; Body weight 15-24kg: 2 tablets; Body weight 25-34kg: 3 tablets; Body weight \> 34kg: 4 tablets; The respective amount of tablets is to be taken at hours 0, 8, 24, 36, 48 and 60 with fatty food.

Based on this trial design, predict the completion outcome and termination type (if applicable).